Molecular characterization of recombinant Pneumocystis carinii topoisomerase I: Differential interactions with human topoisomerase I poisons and pentamidine

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 7, 2002, Pages 2145-2154

  Van Drosst, Rukiyah T ^a   Sanders, Marilyn M ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4',6 DIAMIDINO 2 PHENYLINDOLE; CAMPTOTHECIN; DIMINAZENE ACETURATE; DNA TOPOISOMERASE; HOE 33342; IMIDAZOLE DERIVATIVE; NITIDINE; NOGALAMYCIN; PENTAMIDINE; PROTOBERBERINE; ANTIFUNGAL AGENT; ENZYME INHIBITOR; FUNGAL PROTEIN; RECOMBINANT PROTEIN;

ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME DEGRADATION; GENE SEQUENCE; GENETIC CODE; INHIBITION KINETICS; MOLECULAR BIOLOGY; MOLECULAR CLONING; MOLECULAR WEIGHT; NONHUMAN; NUCLEOTIDE SEQUENCE; PNEUMOCYSTIS CARINII; PRIORITY JOURNAL; AMINO ACID SEQUENCE; DRUG ANTAGONISM; ENZYMOLOGY; GENETICS; HUMAN; METABOLISM; MOLECULAR GENETICS; PNEUMOCYSTIS;

AMINO ACID SEQUENCE; ANTIFUNGAL AGENTS; BASE SEQUENCE; CAMPTOTHECIN; CLONING, MOLECULAR; DNA TOPOISOMERASES, TYPE I; ENZYME INHIBITORS; FUNGAL PROTEINS; HUMAN; MOLECULAR SEQUENCE DATA; PENTAMIDINE; PNEUMOCYSTIS CARINII; RECOMBINANT PROTEINS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; HUMANS; PNEUMOCYSTIS;

EID: 0035984785     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.7.2145-2154.2002     Document Type: Article

References (69)

1. Identification of an N-terminal domain of eukaryotic DNA topoisomerase I dispensable for catalytic activity but essential for in vivo function
2. 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with the human immunodeficiency virus
3. Structure-activity relationships of pentamidine analogs against Giardia lamblia and correlation of antigiardial activity with DNA-binding affinity
4. Structure-activity studies of dicationically substituted bis-benzimidazoles against Giardia lamblia: Correlation of antigiardial activity with DNA binding affinity and giardial topoisomerase II inhibition
5. Apoptosis and its modulation in human promyelocytic HL-60 cells treated with DNA topoisomerase I and II inhibitors
6. Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: Restoration of sensitivity of the cells to the antitumor drug camptothecin
7. Dicationic diarylfurans as anti-Pneumocystis carinii agents
8. Mechanism of catalysis by eukaryotic DNA topoisomerase I
9. DNA topoisomerases: Essential enzymes and lethal targets
10. A new mammalian DNA topoisomerase I poison Hoechst 33342: Cytotoxicity and drug resistance in human cell cultures
11. DNA minor groove-binding ligands: A different class of mammalian DNA topoisomerase I inhibitors
12. In vitro activity of topoisomerase inhibitors against Pneumocystis cannii
13. When good enzymes go bad: Conversion of topoisomerase II to a cellular toxin by antineoplastic drugs
14. A cytotoxicity assay for evaluation of candidate anti-Pneumocystis carinii agents
15. cDNA cloning of human DNA topoisomerase I: Catalytic activity of a 67.7-kDa carboxyl-terminal fragment
16. Selective inhibition of topoisomerases from Pneumocystis carinii compared with that of topoisomerases from mammalian cells
17. Inhibition of topoisomerases from Pneumocystis carinii by aromatic dicationic molecules
18. Isolation of the Pneumocystis carinii Pnetonocystis catind thymidylate synthase gene
19. Crystal structure of a pentamidine-oligonucleotide complex: Implications for DNA-binding properties
20. Activity of topoisomerase inhibitors against Pneumocystis carinii in vitro and in an inoculated mouse model
21. Isolation of six Pneumocystis carinii genes utilizing codon bias
22. Identification of the aminocatechol A-3253 as an in vitro poison of DNA topoisomerase I from Candida albicans
23. Comparison of responses of DNA topoisomerase I from Candida albicans and human cells to four new agents which stimulate topoisomerase-dependent DNA nicking
24. Induction of mammalian DNA topoisomerase I-mediated DNA cleavage and DNA winding by bulgarein
25. Identification of topoisomerase I as the cytotoxic target of the protoberberine alkaloid coralyne
26. Transforming yeast with DNA
27. Differential poisoning of human and Aspergillus nidulans DNA topoisomerase I by bi- and terbenzimidazoles
28. Eukaryotic DNA topoisomerases I
29. Effects of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of AIDS-associated P. carinii pneumonia
30. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells
31. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I
32. DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogs
33. Altered natural history of AIDS-related opportunistic infections in the era of potent combination antiretroviral therapy
34. Dihydropteroate synthase mutations in Pneumocystis carinii associated with sulfa prophylaxis failures
35. Pneumocystis carinii mutations are associated with duration of sulfa or sulfone prophylaxis exposure in AIDS patients
36. A subthreshold level of DNA topoisomerases leads to the excision of yeast rDNA as extrachromosomal rings
37. Mechanisms of camptothecin resistance in yeast DNA topoisomerase I mutants
38. Eukaryotic DNA topoisomerases: Two forms of type I DNA topoisomerases from HeLa cell nuclei
39. Inhibition of in vitro splicing of a group I intron of Pneumocystis carinii
40. Failure of co-trimoxazole in Pneumocystis carinii infection and mutations in dihydropteroate synthase gene
41. Pentamidine inhibition of group I intron splicing in Candida albicans correlates with growth inhibition
42. Major advances in antibacterial quinolone therapy
43. DNA topoisomerase-targeting antitumor drugs can be can be studied in yeast
44. Minor groove-directed and intercalative ligand-DNA interactions in the poisoning of human DNA topoisomerase I by protoberberine analogs
45. The basis for camptothecin enhancement of DNA breakage by eukaryotic topoisomerase I
46. New Drug Developments for opportunistic infections in immunosuppressed patients: Pneumocystis carinii
47. Crystal structure of human topoisomerase I in covalent and noncovalent complexes with DNA
48. Inhibition of epipodophyllotoxin cytotoxicity by interference with topoisomerase-mediated DNA cleavage
49. Drugs affecting trypanosome topoisomerases
50. DNA topoisomerases from pathogenic fungi: Targets for the discovery of antifungal drugs
51. Poisoning of topoisomerases by menogaril and nogalamycin dictated by the minor groove-binding nogalose sugar
52. Topoisomerase inhibitors: A review of their therapeutic potential in cancer
53. The domain organization of human topoisomerase I
54. A model for the mechanism of human topoisomerase I
55. Pneumocystis carinii: What is it, exactly?
56. Use of T7 RNA polymerase to direct expression of cloned genes
57. Synthesis and evaluation of terbenzimidazoles as topoisomerase I inhibitors
58. A new type of DNA minor-groove complex: Carbazole dication-DNA interactions
59. Identification of the gene encoding DNA topoisomerase I from Candida albicans
60. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II
61. Cloning, characterization and sequence of the yeast DNA topoisomerase I gene
62. Analogs of 1,5-bis(4-amidinophenoxy)pentane (pentamidine) in the treatment of experimental Pneumocystis carinii pneumonia
63. Activity of cationically substituted bis-benzimidazoles against experimental Pneumocystis carinii pneumonia
64. A simple, rapid technique for determination of the effects of chemotherapeutic against on mammalian cell-cycle traverse
65. Cloning and sequencing of Schizosaccharomyces pombe DNA topoisomerase I gene, and effect of gene disruption
66. Cloning and characterization of the Aspergillus nidulans DNA topoisomerase I gene
67. DNA minor groove binding-directed poisoning of human DNA topoisomerase I by terbenzimidazoles